1. India Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Vanta Bioscience Ltd.

Vanta Bioscience Ltd.

BBSE:VANTABIO
20.40
INR
-0.02
(-0.10%)
107.75MMarket Cap
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
- -
6.96
19.68
22.41
15.9
15.35
9.94
15.4
1.79
2.55
- -
Basic EPS, GAAP
- -
0.05
1.1
1.59
0.71
0.14
-10.27
-3.67
-4.23
0.15
- -
Free Cash Flow per Basic Share
-0.46
-20.27
-1.64
-7.94
-24.12
-18.86
-46.45
-1.14
-7.01
-17
- -
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
10.74
28.96
35.25
37.18
37.89
38.03
27.75
24.08
16.51
29.77
29.77
Tangible Book Value per Share
10.74
20.47
27.54
29.48
15.93
-5.18
-27.07
-36.57
-54.78
-24.22
-24.22
Basic Weighted Avg Shares
6
6
6
6
6
6
6
6
6
7
7
Sales/Revenue/Turnover
- -
40
124
141
100
97
63
97
11
18
- -
Operating Margin (%)
- -
13.8
24.27
22.49
27.37
22.22
-109.8
-32.58
-186.9
34.77
- -
Depreciation Expense
- -
6
7
12
13
13
27
45
12
12
- -
Net Income, GAAP
- -
- -
7
10
4
1
-65
-23
-27
1
- -
Effective Tax Rate (%)
- -
91.33
36.74
24.52
23.91
41.03
- -
- -
- -
- -
- -
Profit Margin (%)
- -
0.68
5.61
7.1
4.48
0.91
-103.26
-23.82
-236.91
5.96
- -
Working Capital
4
66
138
100
51
2
-25
-56
-112
23
23
LT Debt
75
100
122
137
278
370
471
489
541
312
312
Total Equity
62
166
232
245
262
293
189
130
38
212
212
Return on Invested Capital (%)
- -
0.19
5.06
6.11
4.05
1.86
- -
- -
- -
- -
- -
Return on Capital (%)
- -
0.2
5.32
6.25
3.88
2.32
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
0.24
3.59
4.39
1.9
0.37
-31.22
-14.16
-20.85
0.69
- -

Capital Structure

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
ST Debt
160
76
69
LT Borrowings
541
230
312
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6
7
7
Market Capitalization
140
173
108

Working Capital

INR

•

in mil. unless spec.
Mar'25
Sep'26
Mar'26
Total Current Assets
154
112
141
Cash, Cash Equivalents & STI
2
1
1
Accounts Receivable, Net
25
18
26
Inventories
65
77
75
Total Current Liabilities
266
139
118
Payables & Accruals
- -
- -
- -
ST Debt
160
76
69
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
66.76%
459.71%
Free Cash Flow
- -
142.91%
172.99%
Net Income, GAAP
- -
-1,536.1%
-104.05%
Sales/Revenue/Turnover
- -
-2.22%
61.11%
Total Cash Common Dividend
- -
- -
- -

Semi-annual Revenue

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
97
2025
- -
- -
11
2026
- -
- -
18

Semi-annual Earnings Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
-3.67
2025
- -
- -
-4.23
2026
- -
- -
0.15

Semi-annual Dividends Per Share

INR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
- -
2025
- -
- -
- -
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Dopesh Raja Mulakala
Full Time Employees
38
Sector
Health technology
Industry
Biotechnology
Address
No. 02 Hyderabad TS India 500003
IPO Date
Oct 6, 2017
Website
vantabio.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Vanta Bioscience Limited, an India-based preclinical contract research organization, provides GLP-compliant toxicology and safety assessment services to the pharmaceutical, medical devices, nutraceuticals, feed additives, biotech, agrochemicals, cosmetics, and chemical industries worldwide; core offerings include toxicology studies (genetic, animal, inhalation, and eco-toxicology), agro-chemical and chemical safety assessments, biocompatibility studies, diet formulation, batch release tests, medical devices testing, food additives evaluation, and cosmetics safety testing; the company also delivers risk assessment services for active pharmaceutical ingredients, excipients, extractables, leachables, and pharmaceutical impurities, along with determination of health-based exposure limits such as permitted daily exposure, allowable daily exposure, and occupational exposure limits. Founded in 2016 and headquartered in Secunderabad, Telangana, with operations centered in India and facilities near Chennai, Tamil Nadu, Vanta Bioscience conducts in vitro and in vivo studies compliant with OECD GLP, ISO, and USFDA GLP (21 CFR Part 58) guidelines to support regulatory submissions including IND filings. In recent developments, the company reported audited financial results for the half-year and year ended March 31, 2025, reflecting net losses with an unmodified audit opinion; it previously acquired subsidiaries Vanta Clinical Research Limited and Vayam Research Solutions Limited during 2018-19 to expand preclinical proof-of-concept capabilities, while Vayam ceased to be a step-down subsidiary following DCGI registration grant; additionally, board meetings in 2025 addressed financial approvals amid operational challenges including high debtor days and negative sales growth.